You are here: Industry Insights > cancer

News List

Barriers to Prostate Cancer Research in Black Men Identified drugs
November 01, 2018
Barriers to Prostate Cancer Research in Black Men Identified
Half of kidney cancer patients are initially misdiagnosed, according to data from Kidney Cancer UK’s patient survey. pharmafile
October 31, 2018
Despite being the 7th most common cancer in the United Kingdom, 45% of patients were initially treated for less serious conditions such as urine infections, kidney stones or respiratory problems....
Palbociclib improves patients’ survival in metastatic breast cancer europeanpharmaceuticalreview
October 31, 2018
A Phase III clinical trial has shown that a combination of palbociclib and fulvestrant leads to a longer survival for HR-positive breast cancer…
New epigenetic drug strategy to treat cancer worldpharmanews
October 29, 2018
Researchers have discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes that have been epigenetically silenced by cancer.
Largest census of cancer genes to help understand drug targets worldpharmanews
October 25, 2018
Researchers at the Wellcome Sanger Institute have created the first comprehensive summary of all genes known to be involved in human cancer, the "Cancer Gene Census".
Bayer, Orion drug shows strong results in prostate cancer pharmatimes
October 25, 2018
Bayer and Orion's darolutamide, a novel oral androgen receptor antagonist for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)...
Novartis snaps up cancer drug developer Endocyte for $2.1 billion pharmafile
October 19, 2018
Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology to investigate potential development of therapies in prostate cancer, it has emerged.
JHL Biotech receives China approval for cancer Biosimilar biospectrumasia
October 19, 2018
The proposed bevacizumab biosimilar, JHL1149, treats several forms of cancer, including advanced non-squamous non-small-cell lung cancer (NSCLC), metastatic colorectal cancer, metastatic kidney cancer, advanced cervical cancer and recurrent ovarian cancer
Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field? fiercepharma
October 18, 2018
The old adage “better late than never” may seem tired, but it could be apropos for Pfizer’s newly FDA-approved PARP inhibitor, Talzenna. Pfizer picked up the drug in its $14 billion acquisition of Medivation in 2017, when it ...
US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer biospectrumasia
October 17, 2018
Press Release Lynparza AstraZeneca Merck & Co. FDA Pancreatic Cancer Regulatory Affairs

Previous page 1 2 3 4 5 6 7 8 9 10 ... 88 89 Next page